Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
12/11/25 Azura Ophthalmics AZR-MD-001 for Dry Eye (Ophthalmology) Subscribers Only Subscribers Only Subscribers Only
12/10/25 Johnson & Johnson (JNJ) Tecvayli for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only
12/10/25 Nurix Therapeutics (NRIX) bexobrutideg for Marginal Zone Lymphoma - NHL Subscribers Only Subscribers Only Subscribers Only
12/10/25 Nurix Therapeutics (NRIX) bexobrutideg for Waldenstrom Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL) - NHL Subscribers Only Subscribers Only Subscribers Only
12/10/25 Nurix Therapeutics (NRIX) bexobrutideg for Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/17/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update